The approvals of PARP inhibitors for the treatment of late line ovarian cancer were largely based on objective response rate (ORR) and median duration of response (mDOR), and median overall survival (mOS) data have not yet matured at that time.125–127 Of note, median progression free survival (mPFS) but not mOS are primary endpoints for most clinical trials of PARP inhibitors, which have supported other approvals in ovarian cancer. Here, PARP1 is linked to ovarian cancer.